SUTRO BIOPHARMA, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Sutro Biopharma, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2017 to Q2 2024.
  • Sutro Biopharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $6.16M, a 7.54% decline year-over-year.
  • Sutro Biopharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $24.5M, a 3.41% decline year-over-year.
  • Sutro Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $24.9M, a 5.31% decline from 2022.
  • Sutro Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $26.3M, a 13.2% increase from 2021.
  • Sutro Biopharma, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $23.2M, a 95% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $24.5M $6.16M -$502K -7.54% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $25M $6.07M +$47K +0.78% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $24.9M $6.22M +$371K +6.34% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 $24.5M $6M -$779K -11.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $25.3M $6.66M -$35K -0.52% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $25.4M $6.02M -$953K -13.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $26.3M $5.85M -$1.04M -15% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 $27.3M $6.78M +$287K +4.42% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $27.1M $6.7M +$789K +13.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $26.3M $6.97M +$3.02M +76.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $23.2M $6.89M +$3.8M +123% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-25
Q3 2021 $19.4M $6.5M +$3.38M +109% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $16.1M $5.91M +$2.9M +96.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $13.2M $3.95M +$1.25M +46% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $11.9M $3.09M +$404K +15.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-30
Q3 2020 $11.5M $3.11M +$232K +8.06% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $11.3M $3.01M +$548K +22.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $10.7M $2.71M +$421K +18.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $10.3M $2.68M -$188K -6.56% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $10.5M $2.88M +$2.88M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $7.62M $2.46M +$2.46M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $5.16M $2.29M +$2.29M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 $2.87M $2.87M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-18
Q3 2018 $321* -$272 Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $232* Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $249* Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2017 $593* Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.